Study type: Human research · Status: Verified against declared source

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease

2020

Study scale: The estimation of the sample size has been made taking into account the primary endpoint (i.e., VEGF change from baseline).

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

The estimation of the sample size has been made taking into account the primary endpoint (i.e., VEGF change from baseline).

Key findings

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer’s disease (AD) severity and may prevent cognitive decline.

Limitations and uncertainty

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer’s disease (AD) severity and may prevent cognitive decline.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.